Page 98 - 《中国药房》2024年24期
P. 98
·循证药学·
抗结核药物性肝损伤发生率及其危险因素的Meta分析 Δ
谢琴琴 1, 2* ,季欢欢 ,龚美玲 ,贾运涛 (1.重庆医科大学药学院,重庆 400016;2.重庆医科大学附属儿童医
2 #
2
1, 2
院药学部/国家儿童健康与疾病临床医学研究中心/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国
家国际科技合作基地/儿童感染与免疫罕见病重庆市重点实验室,重庆 400014)
中图分类号 R978.3;R969.3 文献标志码 A 文章编号 1001-0408(2024)24-3052-07
DOI 10.6039/j.issn.1001-0408.2024.24.15
摘 要 目的 系统评价抗结核药物性肝损伤(ATB-DILI)发生率及其危险因素。方法 检索 PubMed、Embase、the Cochrane
Library、Web of Science、中国知网、维普网、万方数据、中国生物医学文献数据库,收集抗结核药物治疗结核后发生ATB-DILI及其
危险因素分析的病例对照研究和队列研究,检索时限为建库至 2024 年 5 月 31 日。筛选文献、提取数据,评价文献质量后,采用
Stata 17.0 软件和 RevMan 5.3 软件进行 Meta 分析。结果 共纳入 26 篇文献,涉及 38 971 例患者,其中 ATB-DILI 患者为 4 106 例。
Meta分析结果显示,ATB-DILI发生率为12.94%[95%CI(10.82%,15.06%),P<0.001];亚组分析显示,在队列研究、中国研究、儿童
患者中ATB-DILI发生率更高(P<0.001)。年龄≥60岁、体重指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不
良、低蛋白血症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高对发生ATB-DILI均有显
著影响(P<0.05)。敏感性分析和发表偏倚分析结果显示,本研究所得结果稳健可靠。结论 结核患者使用抗结核药物治疗后的
ATB-DILI发生率为12.94%;年龄≥60岁、体重指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不良、低蛋白血
症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高均是发生ATB-DILI的危险因素。
关键词 抗结核药;药物性肝损伤;发生率;危险因素;Meta分析
Meta-analysis of the incidence and risk factors of anti-tuberculosis drug-induced liver injury
2
1, 2
1, 2
XIE Qinqin ,JI Huanhuan ,GONG Meiling ,JIA Yuntao (1. School of Pharmacy, Chongqing Medical
2
University, Chongqing 400016, China;2. Dept. of Pharmacy, Children’s Hospital of Chongqing Medical
University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key
Laboratory of Child Development and Disorders/China International Science and Technology Cooperation Base of
Child Development and Critical Disorders/Chongqing Key Laboratory of Child Rare Diseases in Infection and
Immunity, Chongqing 400014, China)
ABSTRACT OBJECTIVE To systematically evaluate the incidence of anti-tuberculosis drug-induced liver injury (ATB-DILI)
and its risk factors. METHODS PubMed, Embase, the Cochrane Library, Web of Science, China Knowledge Network, VIP,
Wanfang data and China Biomedical Literature Database were searched to collect cohort studies and case-control studies on the
incidence and risk factors of ATB-DILI from the establishment of the database to 31 May 2024. After screening literature, extracting
data and evaluating the quality of literature, meta-analysis was performed using Stata 17.0 and RevMan 5.3 software. RESULTS A
total of 26 literature involving 38 971 patients were included, of which 4 106 patients suffered from ATB-DILI. Meta-analysis
showed that the incidence of ATB-DILI was 12.94% [95%CI (10.82%,15.06%), P<0.001]; subgroup analysis showed that the
incidence of ATB-DILI in cohort studies, Chinese studies and pediatric patients was higher (P<0.001). Age≥60 years, abnormal
body mass index, alcoholism, smoking, history of liver disease, hepatitis B surface antigen positivity, extrapulmonary
tuberculosis, malnutrition, hypoproteinemia, cardiovascular disease, diabetes mellitus, systemic lupus erythematosus, no
prophylactic use of hepatoprotective drugs, and high baseline alanine transaminase levels were risk factors for developing ATB-DILI
(P<0.05). Sensitivity analysis and publication bias analysis showed that the results obtained in this study were relatively robust.
CONCLUSIONS The incidence of ATB-DILI in tuberculosis patients is 12.94%. Age≥60 years, abnormal body mass index,
alcoholism, smoking, history of liver disease, hepatitis B surface antigen positivity, extrapulmonary tuberculosis, malnutrition,
hypoproteinaemia, cardiovascular disease, diabetes mellitus,
Δ 基金项目 重庆市科卫联合医学科研项目(No.2022ZDXM020);
systemic lupus erythematosus, non-prophylactic use of
重庆医科大学未来医学青年创新团队发展支持计划项目(No.W0081);
hepatoprotective medications, and high baseline levels of
重庆医科大学研究生智慧医学专项研发计划(No.YJSZHYX202209)
*第一作者 硕士研究生。研究方向:临床药学、药物警戒。 alanine transaminase are the risk factors for developing ATB-
E-mail:2022120924@stu.cqmu.edu.cn DILI.
# 通信作者 主任药师,硕士。研究方向:临床药学、药物警戒。 KEYWORDS antitubercular agents; drug-induced liver
E-mail:jiayuntaomail@hospital.cqmu.edu.cn injury; incidence; risk factors; meta-analysis
· 3052 · China Pharmacy 2024 Vol. 35 No. 24 中国药房 2024年第35卷第24期